Reading SGHT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGHT free→Reading SGHT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGHT free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-15
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral. Earnings quality is unassessable since the company is unprofitable. Management's recent track record has been unsteady. Risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 24% above where it trades (it looks cheap on this basis); the read is fair, but weakening. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $5.02. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $5.02 SGHT trades at 3× p/s, in line with its 3× p/s peer median. Our $7.04 fair value reflects that, medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 29% below a flat-multiple fair value, below our forecast of about 5%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.67x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.17 → $-0.17 (+1.9% / 30d). 1 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 67% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$290.
How much price usually moves either way.
On a bad day, this stock has moved -$648.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,188.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If sector revenue growth picks up, it may benefit Sight Sciences. This could improve overall market conditions.
Confirms:Sector revenue growth exceeds 10% year over year.
Disproves:Sector revenue growth remains below 5% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SGHT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition On May 6, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report").*
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SGHT Sight Sciences, Inc. | Typical Show detailsSector percentile: 41 of 100 | fair | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Sight Sciences has raised its revenue guidance for the full year 2026 to range from $83 million to $89 million.
Stated in 2 of last 2 quarters. Revenue guidance increased from $82-$88M to $83-$89M for 2026. Despite the earnings miss in 2026-Q1, the company remains optimistic about revenue growth, indicating a focus on delivering against the raised guidance.
“Sight Sciences raises its revenue guidance for full year 2026 to range from $83.0 million to $89.0 million.”
“Sight Sciences expects its revenue for full year 2026 to range from $82 million to $88 million.”
The company expects adjusted operating expenses for full year 2026 to range from $93 million to $96 million.
Newly stated in 2025-Q4. Operating expenses guidance set at $93-$96M for 2026. With operating income consistently negative, the company is focusing on managing expenses to improve financial performance, but progress remains to be seen.
Sight Sciences is involved in ongoing litigation with Alcon regarding patent infringement.
Newly stated in 2026-Q1. The company is addressing litigation outcomes with Alcon, as the court preserved a verdict of willful infringement. This ongoing legal matter could impact financial and operational priorities, but no financial impact is quantified yet.
“The U.S. District Court issued an order preserving the jury's verdict of willful infringement in the patent infringement case.”
Regulation FD Disclosure. On April 22, 2026, Sight Sciences, Inc. (the “Company”) received notification that the U.S. District Court for the District of Delaware (the “Court”) entered its final judgment (the “Final Judgment”) regarding the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of the Hydrus® Microstent (“…
Regulation FD Disclosure. On March 30, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing that the U.S. District Court for the District of Delaware (the “Court”) issued an order preserving the jury’s verdict of willful infringement in the patent infringement case (the “Litigation”) filed by the Company in September 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc. (collectively, “Alcon”). The Company had asserted that Alcon’s sale of…
Results of Operations and Financial Condition On March 4, 2026, Sight Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report").*
Entry into a Material Definitive Agreement On January 29, 2026, Sight Sciences, Inc. (the “Company”) entered into that certain Second Amendment to Multi-Tenant Space Lease (the “Second Amendment”) with Deerfield Campbell, LLC (the “Lessor”), for the Company’s headquarters located at 4040 Campbell Avenue (Suites 100 and 120), Menlo Park, California 94025. The Second Amendment amends that certain Multi-Tenant Space Lease, dated February 5, 2021, and that certain Commencement Date/Acceptance Agr…
“The Company expects adjusted operating expenses for full year 2026 to range from $93 million to $96 million.”